(NASDAQ: TNXP) Tonix Pharmaceuticals Holding's forecast annual revenue growth rate of 84.35% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.74%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.61%.
Tonix Pharmaceuticals Holding's revenue in 2026 is $29,102,000.On average, 7 Wall Street analysts forecast TNXP's revenue for 2026 to be $993,009,988, with the lowest TNXP revenue forecast at $872,335,383, and the highest TNXP revenue forecast at $1,170,557,388. On average, 7 Wall Street analysts forecast TNXP's revenue for 2027 to be $1,944,068,570, with the lowest TNXP revenue forecast at $1,395,990,447, and the highest TNXP revenue forecast at $2,683,277,705.
In 2028, TNXP is forecast to generate $3,192,491,607 in revenue, with the lowest revenue forecast at $2,128,613,589 and the highest revenue forecast at $4,177,989,446.